Recombinant adenovirus carrying the hepatocyte nuclear factor‐1alpha gene inhibits hepatocellular carcinoma xenograft growth in mice

Hepatocyte nuclear factor‐1alpha (HNF1α) is one of the key transcription factors of the HNF family, which plays a critical role in hepatocyte differentiation. Substantial evidence has suggested that down‐regulation of HNF1α may contribute to the development of hepatocellular carcinoma (HCC). Herein, human cancer cells and tumor‐associated fibroblasts (TAFs) were isolated from human HCC tissues, respectively. A recombinant adenovirus carrying the HNF1α gene (AdHNF1α) was constructed to determine its effect on HCC in vitro and in vivo. Our results demonstrated that HCC cells and HCC tissues revealed reduced expression of HNF1α. Forced reexpression of HNF1α significantly suppressed the proliferation of HCC cells and TAFs and inhibited the clonogenic growth of hepatoma cells in vitro. In parallel, HNF1α overexpression reestablished the expression of certain liver‐specific genes and microRNA 192 and 194 levels, with a resultant increase in p21 levels and induction of G2/M arrest. Additionally, AdHNF1α inhibited the expression of cluster of differentiation 133 and epithelial cell adhesion molecule and the signal pathways of the mammalian target of rapamycin and transforming growth factor beta/Smads. Furthermore, HNF1α abolished the tumorigenicity of hepatoma cells in vivo. Most interestingly, intratumoral injection of AdHNF1α significantly inhibited the growth of subcutaneous HCC xenografts in nude mice. Systemic delivery of AdHNF1α could eradicate the orthotopic liver HCC nodules in nonobese diabetic/severe combined immunodeficiency mice. Conclusion: These results suggest that the potent inhibitive effect of HNF1α on HCC is attained by inducing the differentiation of hepatoma cells into mature hepatocytes and G2/M arrest. HNF1α might represent a novel, promising therapeutic agent for human HCC treatment. Our findings also encourage the evaluation of differentiation therapy for tumors of organs other than liver using their corresponding differentiation‐determining transcription factor. (HEPATOLOGY 2011)

[1]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[2]  Jun-Ping Zhang,et al.  Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor‐4α gene , 2008, Hepatology.

[3]  Bernard Ducommun,et al.  p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells , 1998, Oncogene.

[4]  W. Xie,et al.  Differentiation therapy with transcription factors might present as an ideal strategy for the treatment of cancer , 2009, Hepatology.

[5]  P. Froguel,et al.  Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. , 1998, The Journal of clinical investigation.

[6]  Kun Wu,et al.  Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma. , 2010, Cancer research.

[7]  K. Kaestner,et al.  Expression of hepatocyte-enriched nuclear transcription factors in mouse liver tumours. , 1996, Carcinogenesis.

[8]  M. Yaniv,et al.  Hepatocyte Nuclear Factor 1 Inactivation Results in Hepatic Dysfunction, Phenylketonuria, and Renal Fanconi Syndrome , 1996, Cell.

[9]  Klaus H. Kaestner,et al.  Targeted Disruption of the Gene Encoding Hepatocyte Nuclear Factor 3γ Results in Reduced Transcription of Hepatocyte-Specific Genes , 1998, Molecular and Cellular Biology.

[10]  A. Giordano,et al.  Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.

[11]  T. Guadagno,et al.  Cdk2 Kinase Is Required for Entry into Mitosis as a Positive Regulator of Cdc2–Cyclin B Kinase Activity , 1996, Cell.

[12]  Fan Zhou,et al.  Analysis of sequence variations in 59 microRNAs in hepatocellular carcinomas. , 2008, Mutation research.

[13]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Duncan,et al.  Mammalian hepatocyte differentiation requires the transcription factor HNF-4alpha. , 2000, Genes & development.

[15]  Z. Ilic,et al.  Hepatocyte Nuclear Factor‐1 as Marker of Epithelial Phenotype Reveals Marrow‐Derived Hepatocytes, but Not Duct Cells, After Liver Injury in Mice , 2008, Stem cells.

[16]  Xin Zhang,et al.  p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. , 2008, Cancer research.

[17]  Kimihiro Hino,et al.  Inducible expression of microRNA-194 is regulated by HNF-1alpha during intestinal epithelial cell differentiation. , 2008, RNA.

[18]  M. Hung,et al.  Unfolded Protein Response Is Required in nu/nu Mice Microvasculature for Treating Breast Tumor with Tunicamycin* , 2011, The Journal of Biological Chemistry.

[19]  R. Costa,et al.  Transcription factors in liver development, differentiation, and regeneration , 2003, Hepatology.

[20]  N. Lazarevich,et al.  Tissue-specific transcription factors in progression of epithelial tumors , 2008, Biochemistry (Moscow).

[21]  R. Medema,et al.  p21 Inhibits Thr161 Phosphorylation of Cdc2 to Enforce the G2 DNA Damage Checkpoint* , 2000, The Journal of Biological Chemistry.

[22]  D. Ovchinnikov,et al.  Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors , 2004, Hepatology.

[23]  Sandrine Imbeaud,et al.  Loss of hepatocyte nuclear factor 1α function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis , 2010, Hepatology.

[24]  G. Giannelli,et al.  Down‐regulation of connective tissue growth factor by inhibition of transforming growth factor β blocks the tumor–stroma cross‐talk and tumor progression in hepatocellular carcinoma , 2010, Hepatology.

[25]  R. Jove,et al.  miR‐194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice , 2010, Hepatology.

[26]  M. Noguchi,et al.  Expression of HNFs and C/EBPα is correlated with immunocytochemical differentiation of cell lines derived from human hepatocellular carcinomas, hepatoblastomas and immortalized hepatocytes , 2003, Cancer science.

[27]  Bei-fang Ning,et al.  Hepatocyte nuclear factor 4α attenuates hepatic fibrosis in rats , 2009, Gut.

[28]  X. Wu,et al.  Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. , 2001, Cancer research.

[29]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[30]  J. Zucman‐Rossi,et al.  Bi-allelic inactivation of TCF1 in hepatic adenomas , 2002, Nature Genetics.

[31]  Nicola J. Rinaldi,et al.  Control of Pancreas and Liver Gene Expression by HNF Transcription Factors , 2004, Science.

[32]  G. Hannon,et al.  Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair , 1994, Nature.

[33]  M. Kasuga,et al.  Expression ratio of hepatocyte nuclear factor-1 to variant hepatocyte nuclear factor-1 in differentiation of hepatocellular carcinoma and hepatoblastoma. , 1996, Journal of hepatology.

[34]  C. de Toma,et al.  Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma. , 2007, Cancer research.

[35]  A. Bosserhoff,et al.  The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma , 2007, Gut.

[36]  S. Sell,et al.  Stem cell origin of cancer and differentiation therapy. , 2004, Critical reviews in oncology/hematology.